NDA 020954 · Otsuka Pharm
Busulfex
Busulfan · Injection
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 11, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 4, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
684
99 Phase 3, 72 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 13, 2003 Supplement 4 · Efficacy · priority review ReviewLetterLabel
- Feb 4, 1999 Original approval · Type 3 - New Dosage Form · priority review ReviewLetterLabel
1 products under this application
- BUSULFEX · BUSULFAN 6MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Busulfan" as an intervention, any sponsor and status, largest first.
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00004128 · 2,000 participants (planned) · Start Sep 1999 · Primary completion Jan 2008
Drug: aldesleukin; filgrastim and 5 more · For: Leukemia
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002549 · 1,520 participants (planned) · Start Nov 1993
Drug: filgrastim; busulfan and 7 more · For: Leukemia
Sites: Innsbruck, Austria; Antwerp, Belgium; Bruges, Belgium · 75 sites in all
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaPivotal-lookingStatus unknown
University of LeicesterAcademic, hospital or other
NCT00020566 · 1,200 participants (planned) · Start Feb 2001 · Primary completion Dec 2011
Drug: dactinomycin; busulfan and 5 more · For: Sarcoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 103 sites in all
- Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaPivotal-lookingStatus unknown
III. Medizinische Klinik MannheimAcademic, hospital or other
NCT00025402 · 1,000 participants (planned) · Start Jul 1997
Drug: filgrastim; recombinant interferon alfa and 6 more · For: Leukemia
Sites: Brno, Czechia; Aachen, Germany; Aalen, Germany · 188 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H, Locatelli F, Sharma A, et al. · N Engl J Med 2024 · Multicenter Study, Clinical Trial, Phase III
- Lentiviral Gene Therapy for Artemis-Deficient SCID.
Cowan MJ, Yu J, Facchino J, et al. · N Engl J Med 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.
Gori JL, Haddad E, Frangoul H, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.
Locatelli F, Thompson AA, Kwiatkowski JL, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- [Ranimustine].
Masaoka T · Gan To Kagaku Ryoho 1990 · Clinical Trial, Comparative Study
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.